Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA)

Trial Identifier: ACT17209
Sponsor: Sanofi
Start Date: December 2021
Primary Completion Date: May 2024
Study Completion Date: December 2029
Condition: Anemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Austria Vienna, Austria, 1140
China Beijing, China, 100005
China Tianjin, China, 300020
Denmark Odense, Denmark, 5000
GERMANY Essen, GERMANY, 45147
Hungary Szekesfehervar, Hungary, 8000
Italy Avellino, Italy, 83100
Italy Meldola, Italy, 47014
Italy Milan, Italy, 20149
Spain Barakaldo, Spain, 48093
Spain Barcelona, Spain, 08036
Spain Madrid, Spain, 28046
Spain Sevilla, Spain, 41013
United Kingdom Leeds, United Kingdom, LS9 7TF
United Kingdom London, United Kingdom, E1 2ES
United Kingdom London, United Kingdom, W2 1NY
United States, California Cerritos, California, United States, 90703
United States, California Glendale, California, United States, 91204
United States, California Long Beach, California, United States, 90805
United States, California Los Angeles, California, United States, 90033
United States, California Santa Ana, California, United States, 92705
United States, California Torrance, California, United States, 90502
United States, California Whittier, California, United States, 90602
United States, District of Columbia Washington, District of Columbia, United States, 20007
United States, Florida Tamarac, Florida, United States, 33321
United States, Massachusetts Boston, Massachusetts, United States, 02114
UNITED STATES, California Cerritos, California, UNITED STATES, 90703